Compare KWR & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | ARWR |
|---|---|---|
| Founded | 1918 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 9.6B |
| IPO Year | 1985 | 1993 |
| Metric | KWR | ARWR |
|---|---|---|
| Price | $137.74 | $70.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $149.25 | $60.70 |
| AVG Volume (30 Days) | 119.2K | ★ 3.2M |
| Earning Date | 10-30-2025 | 11-25-2025 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,864,242,000.00 | $829,448,000.00 |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.08 | ★ 23258.15 |
| 52 Week Low | $95.91 | $9.57 |
| 52 Week High | $155.74 | $72.36 |
| Indicator | KWR | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 76.76 |
| Support Level | $132.16 | $60.29 |
| Resistance Level | $139.30 | $72.36 |
| Average True Range (ATR) | 4.61 | 5.14 |
| MACD | 0.53 | 1.44 |
| Stochastic Oscillator | 59.24 | 92.98 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.